Each case study below represents a moment where better intelligence produced a materially different — and better — strategic outcome.
Ophthalmology BiotechCompetitive Intelligence
HCP Landscape Intelligence Enabling AstraZeneca Acquisition
The intelligence: competitor HCP engagement models were fragmented, leaving KOL advocacy underdeveloped and clinical differentiation uncommunicated at the investigator level.
LucidBio mapped the competitive HCP and KOL landscape for an early-stage ophthalmology biotech, identifying the engagement gap that was limiting trial visibility and investor confidence ahead of acquisition discussions.
Strategic Outcome
Trial enrollment accelerated 35%. Recruitment targets met three months early. Company positioned centrally in AstraZeneca acquisition discussions and valuation supported by clinical momentum data.
Mid-Size Pharma · AMLRegulatory Intelligence
Unified Evidence Strategy Ahead of FDA Submission
The intelligence: internal data interpretation was fragmented across functions, creating regulatory confidence risk — not a data problem, a strategic alignment problem.
LucidBio delivered a cross-functional evidence strategy that unified clinical, biomarker, and regulatory narratives for an AML programme approaching FDA submission — resolving interpretive discrepancies before they became regulatory friction.
Seed-Stage Oncology · EURegulatory Intelligence
EMA Pathway Intelligence That Preserved the Programme
The intelligence: the proposed Phase II protocol carried a 6-month delay risk that competitive precedent analysis and CHMP pathway mapping could resolve before Scientific Advice.
LucidBio delivered a three-pillar regulatory intelligence brief — endpoint precedent analysis, population strategy mapping, and SAP alignment — that repositioned a seed-stage oncology startup's Phase II strategy ahead of EMA Scientific Advice.
Strategic Outcome
Scientific Advice validated the revised strategy. 6-month delay avoided. Company runway and investor timeline preserved.
Large Pharma · OncologyRegulatory Intelligence
Global Regulatory Landscape for BLA with Breakthrough Therapy Designation
The intelligence: multi-agency submission strategies for BTD programmes vary significantly — mapping FDA, EMA, Swiss Medic, and PMDA precedents revealed the optimal sequencing and briefing architecture.
LucidBio provided competitive regulatory intelligence across all four major agencies, mapping precedent programmes, submission sequencing strategies, and BTD-specific engagement patterns to inform the global submission architecture.
Strategic Outcome
All regulatory milestones achieved across four agencies. BTD benefits fully leveraged. Programme timeline accelerated.
Late-Stage BiologicsStrategic Intelligence
Five-Workstream Intelligence Map for BLA-Stage Biologic
The intelligence: five simultaneous submission-critical workstreams were operating without a shared intelligence picture — creating misalignment risk at the worst possible moment.
LucidBio mapped interdependencies across commercial alignment, CMC site validation, BIMO inspection readiness, companion diagnostic regulatory sync, and alliance data integration — providing a single strategic intelligence layer across all five workstreams.
Strategic Outcome
BLA programme restored to track. Full strategic visibility across all five workstreams. Inspection-ready posture established ahead of schedule.
Startup · RadiopharmaceuticalsCompetitive Intelligence
Regulatory & Competitive Landscape for Novel Radiopharmaceutical IND
The intelligence: no precedent map existed internally for a novel radiopharmaceutical mechanism — understanding what FDA had accepted for comparable FIH programmes was the strategic foundation.
LucidBio built the competitive regulatory intelligence picture for a first-in-human radiopharmaceutical programme — mapping FDA precedent programmes, IND clearance patterns, and FIH design benchmarks.
Strategic Outcome
Phase 1 IND cleared by FDA. First-in-human study initiated on schedule. Strategic regulatory foundation established for ongoing programme development.
